Recombinant ADAMTS13

Phase 1Small molecule

Recombinant ADAMTS13 is one of 17 small molecule programs targeting Thrombotic Thrombocytopenic Purpura. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thrombotic Thrombocytopenic PurpuraActive, not recruiting

Thrombotic Thrombocytopenic PurpuraPhase 1

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Thrombotic Thrombocytopenic Purpura

#DrugCompanyPhaseTrials

Bayer Aspirin

Medrol

Neoral

1 4

Rayos

RRoxane Laboratories

Phase 3

1 5

Rituxan

Roche

Phase 2

5 6

Plasma Exchange

Sanofi

Phase 3

1 7

Danocrine

Sanofi

Phase 2

1 8

Vyvgart

Argenx

Phase 2

1 9

Immunosuppressive Treatment

Sanofi

Phase 3

1 10

Anti-CD20 Antibody

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2032

Recruiting

Thrombotic Thrombocytopenic Purpura

NCT06441578

Clinical

Trials by Indication[1]

Thrombotic Thrombocytopenic Purpura2 trials

Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

Completed·BBaxalta now part of Shire·Phase 1·NCT02216084·16 enrolled

A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Recruiting· Takeda logo

Takeda··NCT06441578·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Recombinant ADAMTS13. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant ADAMTS13 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant ADAMTS13. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Takeda

Recombinant ADAMTS13

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2032

Trials by Indication[1]

Thrombotic Thrombocytopenic Purpura2 trials

References

Drug Info

Quick Facts

Related News